Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia
Archiv der Pharmazie · 2025-05 · 358 (5)
DOI: 10.1002/ardp.70005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 09.05.2025. Verfasst von Ayca Irgit und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-abl, Antineoplastic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This study was supported by Health Institutes of Türkiye (TUSEB) under the Grant Number 24333. The authors thank to TUSEB for their supports. Co-funded by the….
Abstract (Originalsprache)
Abelson (ABL1) tyrosine kinase is an essential component of non‐receptor tyrosine kinases and is associated with numerous cellular processes, including differentiation and proliferation. The structural features of ABL1 include a distinct N‐terminal cap region, a C‐terminal tail, a bilobed kinase, SH2, and SH3 domains. These domains enable its engagement in several signaling cascades and dynamic control. The pathophysiology of chronic myeloid leukemia (CML) is mainly driven by the BCR‐ABL1 oncoprotein, arising from dysregulation of ABL1 kinase, namely through its fusion to the breakpoint cluster region (BCR) gene. ABL1 is a crucial target in the treatment of CML as the BCR‐ABL1 fusion causes uncontrolled cellular proliferation and resistance to apoptosis. Tyrosine kinase inhibitors (TKIs) targeting the ABL1 tyrosine kinase are playing a critical role in the treatment of CML through the inhibition of persistently activated signaling pathways mediated by the BCR‐ABL1 fusion protein. The article examines the structural characteristics of ABL1, how they relate to CML, and the interactions between ABL1 and the current FDA‐approved TKIs, emphasizing the kinase's critical function in carcinogenesis and its possible target status for tyrosine kinase inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir, Turkey.
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Chemistry, Faculty of Science, Istanbul University, Fatih, İstanbul, Turkey.
- Department of Drug Discovery, Science Farm Ltd., Kumamoto, Japan.
- Department of Molecular Biology and Genetics, Burdur Mehmet Akif Ersoy University, Burdur, Turkey.
Förderung
- This study was supported by Health Institutes of Türkiye (TUSEB) under the Grant Number 24333. The authors thank to TUSEB for their supports. Co-funded by the…
Zitieren
APA
Irgit, A., Kamıs, R., Sever, B., Tuyun, A. F., Otsuka, M., Fujita, M., Demirci, H., & Ciftci, H. (2025). Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia. Archiv der Pharmazie, 358(5). https://doi.org/10.1002/ardp.70005
Vancouver
Irgit A, Kamıs R, Sever B, Tuyun AF, Otsuka M, Fujita M, et al. Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia. Archiv der Pharmazie. 2025;358(5). doi:10.1002/ardp.70005
BibTeX
@article{Irgit2025,
author = {Irgit, Ayca and Kamıs, Reyhan and Sever, Belgin and Tuyun, Amaç Fatih and Otsuka, Masami and Fujita, Mikako and Demirci, Hasan and Ciftci, Halilibrahim},
title = {Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia},
journal = {Archiv der Pharmazie},
year = {2025},
volume = {358},
number = {5},
doi = {10.1002/ardp.70005}
}
EUVIMED